Mayo Clinic Phoenix

Running trials

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Source

• Recruiting

  Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

  NCT07069738· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06973187· Phase 3· Source

• Recruiting

  A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

  NCT06720987· Phase 1· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Source

• Recruiting

  Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  NCT06479135· Phase 3· Source

• Recruiting

  Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

  NCT06056830· Phase 3· Source

• Active, not recruiting

  A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

  NCT06005740· Phase 1· Source

• Recruiting

  A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  NCT05735184· Phase 1· Source

• Active, not recruiting

  Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

  NCT05683691· Source

• Recruiting

  PROMs After Pancreatectomy

  NCT07173257· Source

• Recruiting

  Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

  NCT03860883· Source

• Recruiting

  Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

  NCT03435796· Phase 2/3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukemia1 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Heart failure1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Multiple myeloma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting
• Sarcoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  Strategy for Improving Stroke Treatment Response

  NCT05948566· Phase 2· Source

• Recruiting

  A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  NCT05006716· Phase 1/2· Source

• Completed

  A Trial Evaluating TG4050 in Ovarian Carcinoma.

  NCT03839524· Phase 1· Source

• Completed

  Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

  NCT02831959· Phase 3· Source